Why Vascular Solutions Is Poised to Outperform

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Vascular Solutions (NASDAQ: VASC  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Vascular and see what CAPS investors are saying about the stock right now.

Vascular facts

Headquarters (founded)

Minneapolis, Minn. (1996)

Market Cap

$273.3 million


Health care supplies

Trailing-12-Month Revenue

$102.6 million


Co-Founder/CEO Howard Root
CFO James Hennen

Return on Equity (average, past 3 years)


Cash / Debt

$19.7 million / $0


Abbott Labs
Johnson & Johnson

Sources: S&P Capital IQ and Motley Fool CAPS.

Just yesterday, CAPS member rknapton succinctly summed up the Vascular outperform case for our community: "Long. Medical instruments company. Nice steady growth. Buying back stock. Cash flow from operating activities growing. Earnings grew 17% on a 9% boost in revenues last quarter. Not bad here at 21x fwd estimates."

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Vascular may not be your top choice.

Your financial health is just as important as your personal health. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.

Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 13, 2013, at 4:35 PM, MedtechInsider wrote:

    VSI may outperform in the short run, but (in my opinion) it will tank in the long run for the following reasons:

    A large amount of its profits are from two devices, and the rest are from a multitude of small devices that do about $1 million in sales annually. This is bad for two reasons. The first is that those two devices could fail (in production, competition, ect) and then you're out a significant portion of the profits. The second is that VSI is wasting time and resources on these small products. VSI already outsources a significant portion of its manufacturing, and that cuts into the margins and outsourcing has cost the company with major recalls.

    One of its flagship products, which accounts for VSI's rapid growth, now has a competing device made by BSX. Yes, VSI is suing BSX for patent infringement, but I foresee VSI losing this battle big time. VSI will then loose control of that segment, and from there the decent will be rapid.

    While VSI does have some talented people, it has more blind leading the blind than it should, and its engineering staff is lacking in some very key areas. I've seen this first hand, and this should be a major concern.

    For these reasons the stock is over valued, the company is overestimated in ability, and the investment base is being led down a bad path by CEO Howard Root. Only bad things can happen, and you should sell while you still can (in my opinion).

  • Report this Comment On April 17, 2014, at 5:20 PM, chris293 wrote:

    VASC is Vascular Solutions Inc. (VSI) one and the same running with the big dogs of medicine and doing a pretty good job of it or so I think. But thanks to the prior comment I will look again. Maybe I'll buy or maybe I'll sell. The over 20% ROE with no debt and the coverage by the S&P will help me balance out my decision.

  • Report this Comment On October 23, 2014, at 5:50 PM, chris293 wrote:

    Earlier this year I sold some VASC for a profit and replaced those shares on a dip and ended up with a real positive gain. And what I said in April is still true. And the prior comment to my prior comment is not, it seems even talking about VASC when he is saying 'VSI' more than once, but he did have the right CEO, H. Root for VASC. Of course, these comments are somewhat dated.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2607193, ~/Articles/ArticleHandler.aspx, 9/27/2016 3:19:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
VASC $48.79 Down -0.77 -1.55%
Vascular Solutions CAPS Rating: ****
ABT $41.68 Down -0.51 -1.21%
Abbott Laboratorie… CAPS Rating: *****
JNJ $117.78 Down -1.03 -0.87%
Johnson and Johnso… CAPS Rating: *****
MDT $86.56 Down -1.15 -1.31%
Medtronic CAPS Rating: *****